Drug Trial Radar · NCT06387628
LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
Last checked: Nov 19, 2026Latest source record: Aug 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
74
Planned (sponsor's estimate)
Start
Jul 10, 2024
Primary completion
Apr 1, 2026
Study completion Apr 1, 2027
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of LM108 plus toripalimab plusnab-paclitaxel or eribulin as first-line or post-line treatment in patients with metastatic triple-negative breast cancer.
Conditions
- TNBC - Triple-Negative Breast Cancer
Interventions
LM-108Drug
LM-108, 10mg/kg, d1, q6w
ToripalimabDrug
Toripalimab, 240 mg, d1, q3w
EribulinDrug
Eribulin 1.4 mg/m2, d1, 8 , q3w
Nab paclitaxelDrug
Nab paclitaxel 125 mg/m2, d1, 8 , q3w
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: 6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.